Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward C Keystone

Showing results (141-150 of 159) with videos related to

Pageof 16
Sort By:
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
Clinical Therapeutics|July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Plos One|August 25, 2015
Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH)Cheryl Barnabe, Ye Sun, Gilles Boire, et al.
Arthritis and Rheumatism|April 1, 2009
CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian populationErin J Walker, Gideon M Hirschfield, Chun Xu, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Arthritis and Rheumatism|July 13, 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese, Joan M Bathon, Richard W Martin, et al.
Annals of the Rheumatic Diseases|April 25, 2009
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008Monika Schoels, Daniel Aletaha, Josef S Smolen, et al.
The New England Journal of Medicine|February 16, 2017
Baricitinib versus Placebo or Adalimumab in Rheumatoid ArthritisPeter C Taylor, Edward C Keystone, Désirée van der Heijde, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Pageof 16

Showing results (141-150 of 159) with videos related to

Sort By:
Pageof 16
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
Clinical Therapeutics|July 16, 2003
Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot studyMichael H Weisman, Larry W Moreland, Daniel E Furst, et al.
Plos One|August 25, 2015
Heterogeneous Disease Trajectories Explain Variable Radiographic, Function and Quality of Life Outcomes in the Canadian Early Arthritis Cohort (CATCH)Cheryl Barnabe, Ye Sun, Gilles Boire, et al.
Arthritis and Rheumatism|April 1, 2009
CTLA4/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian populationErin J Walker, Gideon M Hirschfield, Chun Xu, et al.
RMD Open|October 8, 2020
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinibJonathan Kay, Masayoshi Harigai, Josh Rancourt, et al.
Arthritis and Rheumatism|July 13, 2002
Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomesMark C Genovese, Joan M Bathon, Richard W Martin, et al.
Annals of the Rheumatic Diseases|April 25, 2009
Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008Monika Schoels, Daniel Aletaha, Josef S Smolen, et al.
The New England Journal of Medicine|February 16, 2017
Baricitinib versus Placebo or Adalimumab in Rheumatoid ArthritisPeter C Taylor, Edward C Keystone, Désirée van der Heijde, et al.
Modern Rheumatology|August 3, 2022
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week resultsYoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Modern Rheumatology|December 15, 2021
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi, et al.
Pageof 16